Search citation statements

Order By: Relevance
Select...
3
1
1
0
16
1

Year Published

2017
2017
2019
2019

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

0
16
1
Order By: Relevance
“…However, contrary to our hypothesis, MDA-MB-231 and MDA-MB-468 cell line endogenously express a mutation in p53 [49]. A mutation in p53 does not function as a tumor suppressor [50, 51]. Additionally, we identified MDM2 protein expression that regulates p53 protein.…”
Section: Discussioncontrasting
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…However, contrary to our hypothesis, MDA-MB-231 and MDA-MB-468 cell line endogenously express a mutation in p53 [49]. A mutation in p53 does not function as a tumor suppressor [50, 51]. Additionally, we identified MDM2 protein expression that regulates p53 protein.…”
Section: Discussioncontrasting
“…Yet, the p53 transcriptional response does not necessarily lead to apoptosis, and it may, instead, favour tumour persistence [44,45]. Efforts to activate and regulate cytoplasmic p53 function may, in parallel, lead to the development of alternative strategies of p53-centred anticancer therapy [46][47][48].…”
Section: Discussionmentioning
“…These tumors usually are more aggressive and resistant to treatment. The compounds that can restore wild type p53 activity have been summarized in several recent reviews [12, 116, 117]. Among all the compounds, PRIMA-1 [2,2-bis (hydroxymethyl)-3-quinuclidinone] is the most well-advanced small molecule [117, 118].…”
Section: Therapeutic Strategies To Target Mutant P53mentioning